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Abstract
The aim of this study was to report 3-year outcomes of toxicity, cosmesis, and
local control using a once daily fractionation scheme (49.95 Gy in 3.33 Gy once
daily fractions) for accelerated partial breast irradiation (APBI) using three-
dimensional conformal radiotherapy (3D-CRT). Between July 2008 and August
2010, women aged ≥40 years with ductal carcinoma in situ or node-negative
invasive breast cancer ≤3 cm in diameter, treated with breast-conserving surgery
achieving negative margins, were accrued to a prospective study. Women were
treated with APBI using 3–5 photon beams, delivering 49.95 Gy over 15 once
daily fractions over 3 weeks. Patients were assessed for toxicities, cosmesis, and
local control rates before APBI and at specified time points. Thirty-four
patients (mean age 60 years) with Tis 0 (n = 9) and T1N0 (n = 25) breast can-
cer were treated and followed up for an average of 39 months. Only 3% (1/34)
patients experienced a grade 3 subcutaneous fibrosis and breast edema and 97%
of the patients had good/excellent cosmetic outcome at 3 years. The 3-year rate
of ipsilateral breast tumor recurrence (IBTR) was 0% while the rate of contra-
lateral breast events was 6%. The 3-year disease-free survival (DFS), overall sur-
vival (OS), and breast cancer-specific survival (BCSS) was 94%, 100%, and
100%, respectively. Our novel accelerated partial breast fractionation scheme of
15 once daily fractions of 3.33 Gy (49.95 Gy total) is a remarkably well-toler-
ated regimen of 3D-CRT-based APBI. A larger cohort of patients is needed to
further ascertain the toxicity of this accelerated partial breast regimen.
Introduction
Accelerated partial breast irradiation (APBI) is being
explored as an alternative option in lieu of whole-breast
irradiation after breast-conserving surgery (BCS) in
selected patients with early-stage breast cancer. The goal
of APBI is to deliver higher doses per fraction of radia-
tion in a short period of time (twice daily for 5 days) to
the tumor bed with an additional margin. In addition to
its convenience, advocates state that APBI may reduce
fatigue while improving cosmesis and quality-of-life. APBI
may be delivered using multi-catheter interstitial
brachytherapy, balloon catheter brachytherapy, three-
dimensional conformal external beam radiotherapy (3D-
CRT), and intra-operative radiotherapy. However, given
the widespread presence of linear accelerators in the Uni-
ted States, 3D-CRT-based APBI is the most prevalent
form of APBI used for treatment of these early-stage
breast cancer patients.
The NSABP B-39/RTOG 0413 trial utilizes a 385 cGy
BID 9 5 days fractionation scheme and several single-
institution studies report of an excess of fair/poor cos-
metic outcomes and adverse events delivering this APBI
regimen using 3D-CRT [1, 2]. Accordingly, while this
fractionation scheme is the most commonly used schedule
in the United States, the optimum fractionation scheme
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for APBI using 3D-CRT has not yet been determined and
there is a paucity of published data for other fractionation
schemes for APBI using 3D-CRT.
Recent data have suggested that women prefer a once
daily course of radiotherapy as compared to twice daily
radiation, even if the latter is of shorter total duration. A
study by Hoopes et al. [3] found that patient treatment
preferences by fractionation/volume scheme were as fol-
lows: shortened whole-breast radiation therapy (RT) (e.g.,
4256 cGy in 16 fractions) 62%, APBI (twice daily for
5 days) 28%, and conventional whole-breast irradiation
10%. A total of 71% of women would prefer once daily
RT over 10 days versus twice daily RT over 5 days. When
evaluating various PBI strategies, they reported that 62%
of women preferred APBI using 3D-CRT versus 38% who
would prefer brachytherapy-based APBI. While a short-
ened, twice daily over 5 days APBI regimen may be
attractive to some patients, one can understand why both
a patient and a radiotherapy department would prefer a
once daily APBI regimen, albeit one that is slightly longer
in total duration. To date, the majority of the reports on
outcomes and toxicity of 3D-CRT-based APBI have trea-
ted patients using 3.85 cGy per fraction delivered twice
daily for 5 days and reports of alternative fractionation
schemes for 3D-CRT-based APBI are scant.
CINJ 040801 was an IRB-approved, single-arm, pro-
spective trial investigating the utility of gold fiducial
markers in APBI using 3D-CRT; patients were treated
with a once daily hypofractionated fractionation scheme
(333 cGy 9 15 single daily fractions). The purpose of this
study was to perform an analysis of the treatment-related
toxicities, cosmesis, and local control rates at 3 years of a
once daily fractionation scheme for APBI using 3D-CRT
in patients with early-stage, node-negative breast cancer.
Material and Methods
Patient eligibility
This protocol received IRB approval on 17 July 2008.
Patients were identified preoperatively as being candidates
from July 2008 to August 2010. Preoperative eligibility
criteria included age ≥45 years, ductal carcinoma in situ
or invasive histologies, clinical tumor size ≤3 cm, and
clinically node-negative. Patients (n = 45) who consented
for the trial, underwent definitive surgical resection with
fiducial marker placement. Axillary evaluation was per-
formed for all patients with invasive histologies. Patients
received 4–6 gold fiducial markers (CIVCO Medical Solu-
tions, Kalona, IA) during the definitive surgical proce-
dure. Each gold fiducial marker is 2 mm in diameter and
is attached to 2/0 prethreaded proline suture; these were
sutured to the superior, inferior, medial, lateral, and pos-
terior walls of the surgical cavity. Patients were enrolled
on trial if the final pathologic review was appropriate
(n = 34). Additional final eligibility criteria included neg-
ative margins as defined by the NSABP, pathologically
node negative, unifocal disease, delivery of APBI prior to
any systemic therapy, simulation between 14 and 60 days
from date of last surgery, initiation of radiation within
15–80 days of date of last surgery. Patients with positive
margins underwent reexcision to obtain clear margins
and underwent additional placement of gold markers.
Radiation treatment planning
All patients received RT to their breast based on the
established partial breast guidelines set forth by the Radia-
tion Therapy Oncology Group (RTOG). Postoperatively,
each patient underwent computed tomography (CT) sim-
ulation to obtain 3D anatomy data for treatment plan-
ning purposes. During the simulation, each patient lay
supine on a breast board with both arms above their head
on the CT couch. After the scan acquisition, images were
transferred to the Varian EclipseTM Treatment Planning
System (TPS, Version 7.3.10; the Varian Medical System,
Palo Alto, CA) where target delineation, isocenter place-
ment, beam placement, and treatment planning were per-
formed. Normal structures were delineated and they
included the thyroid, ipsilateral whole breast, contralateral
whole breast, lungs, and heart. The NSABP B-39/RTOG
0413 APBI protocol base their target volumes on the
postoperative seroma cavity as defined on the planning
CT scan [4, 5]. The surgical cavity is defined on CT scan
and an expansion of 1.5 cm is added to form the clinical
target volume (CTV). The CTV is then restricted to
within the lung–chest wall interface and 5 mm of the skin
surface; an additional 1.0 cm margin is provided to form
the planning target volume (PTV). The PTV then
excluded the pectoralis muscles, chest wall and the first
5 mm beneath the skin to form the planning target
volume-evaluation (PTV_EVAL).
Typically, a 3-, 4-, or 5-field noncoplanar photon
beams were used (Fig. 1); electrons were used to supple-
ment dose in two patients given the medial location of
the seroma cavity in their left breast. All patients were
treated in the supine position. The following dosimetric
constraints were used to evaluate plans: <60% of the
whole-breast reference volume received ≥50% of the pre-
scribed dose and <35% of the whole-breast reference vol-
ume received the prescribed dose. The contralateral breast
reference volume received <3% of the prescribed dose to
any point. Less than 15% of the ipsilateral lung received
30% of the prescribed dose while less than 15% of the
contralateral lung received 5% of the prescribed dose. For
right-sided lesions, <5% of the heart received 5% of the
ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 965
S. Goyal et al. Three-Year Outcomes of Once Daily APBI
prescribed dose while for left-sided lesions, <40% of the
heart received 5% of the prescribed dose. The maximum
dose to the thyroid: was 3% of the prescribed dose.
Radiotherapy fractionation design
Patients were treated using a APBI fractionation scheme:
49.95 Gy over 15 single daily fractions; this was based on
the hypofractionated whole-breast dose-fractionation used
by Owens et al.: 42.9 Gy over 13 fractions delivered to
the whole breast followed by a 14 Gy boost in seven frac-
tions (Table 1). Assuming an a/b ratio of 4 Gy for tumor
kill, 91.5 Gy4, 90 Gy4, and 99.2 Gy4 was estimated to be
delivered using our fractionation scheme, standard
WBI + boost, and the Owens fractionation, respectively.
Assuming an a/b ratio of 10 Gy for acute effects,
66.6 Gy10, 72 Gy10, and 73.9 Gy10 was estimated to be
delivered using our fractionation scheme, standard
WBI + boost, and the Owens fractionation, respectively.
Toxicity analysis
Standard baseline evaluation included a complete medical
history; physical examination, including performance
status; and radiologic and pathologic assessments. Patients
were evaluated weekly during the course of radiotherapy,
3–4 weeks after completion of treatment, and then at
3–6 month intervals thereafter. To gather information
regarding loco-regional toxicities, charts were reviewed
for toxicities before, during, and after radiotherapy. Tox-
icities, including Pericarditis, pneumonitis, radiation
recall, infection, fatigue, radiation dermatitis, symptom-
atic seroma, hyperpigmentation, edema, fibrosis, brachial
plexopathy, rib fracture, fat necrosis, and chest wall pain,
were scored using the Common Terminology Criteria for
Adverse Events (CTCAE, v4.0). In this system, sequelae
are graded from mild (grade 1) to fatal (grade 5). Patients
were considered to have a significant complication if they
had a toxicity of grade 3 or higher. In cases in which a
complication could have been the result of surgical proce-
dure and/or radiation toxicity, it was coded as radiation
toxicity unless such symptoms predated the radiation
treatment. The Harvard Cosmesis Scale was used to deter-
mine the cosmetic outcome of the treated breast; in this
scale, the untouched contralateral breast serves as the
patients’ reference [6].
Statistical methods
Standard statistical methods using Version 9.2 of the SAS
statistical software package (SAS, Cary, NC) was utilized
to analyze all data. All time intervals were calculated from
the date of last radiotherapy. Descriptive analyses were
used to show the proportion of patients with grade 0,
grade 1, and grade 2+ events at each follow-up visit. All




A total of 45 patients underwent lumpectomy with fidu-
cial marker placement between July 2008 and August
2010; five (11%) patients became ineligible due to nodal
positivity, one (2%) patient due to persistent positive
Figure 1. Typical beam arrangement for three-dimensional conformal
radiotherapy (3D-CRT)-based accelerated partial breast irradiation
(APBI).














Traditional WB + 10 Gy boost
2 Gy 9 30 = 60 Gy
72 Gy10 90 Gy4 100 Gy3
Lancet fract + boost
3.3 Gy 9 13 = 42.9 Gy
2 Gy 9 7 = 14 Gy
73.9 Gy10 99.2 Gy4 113 Gy3
RTOG/NSABP B39
3.85 Gy 9 10 = 38.5 Gy
53.3 Gy10 75.6 Gy4 88 Gy3
CINJ fractionation
3.33 Gy 9 15 = 49.95 Gy
66.6 Gy10 91.5 Gy4 105 Gy3
RTOG, Radiation Therapy Oncology Group.
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margins, two (4%) patients due to large tumor size, and
three (7%) patients due to other reasons (Fig. 2). The
mean number of fiducial markers placed at the time of
surgery was four (range 4–6).
Patient characteristics
Thirty-four patients (mean age 60 years) with Tis 0
(n = 9) and T1N0 (n = 25) breast cancer with negative
margins and negative lymph nodes continued onto APBI
prior to initiation of any systemic (cytotoxic or hor-
monal) therapy (Table 2). The median patient age was 61
(range 46–83) and the median tumor size was 1.1 cm
(range 0.3–2.7). Three of the 25 patients with invasive
cancer were ER/PR-negative and Her2-positive, one
patient was ER/PR/HER2-positive, and one patient was
triple negative. Based on the ASTRO consensus guidelines
on APBI treated outside the context of a clinical trial, 19
patients fall into the suitable category, 12 patients fall into
the cautionary subgroup (eight with DCIS and four with
ER negativity), and three patients would have been classi-
fied in the unsuitable category (age <50) [7].
The mean time from date of last surgery to date of
simulation was 28 days (range 14–59) while the mean
times from simulation to start and completion of RT
were 11 days (range 4–19) and 31 days (range 22–40),
respectively. The mean length of RT was 20 days (range
18–23). The median follow-up for all patients is 1173 days
(range 664–1601), or 39.1 months. Table 3 contains the
dosimetric characteristics of the study population.
Treatment efficacy
The 3-year rate of ipsilateral breast tumor recurrence
(IBTR) was 0% while the rate of contralateral breast
events was 6%; two patients with intraductal carcinoma
who did not receive hormonal therapy developed a con-
tralateral intraductal carcinoma 2 years after their initial
diagnosis. One patient with a remote history of stage I
melanoma developed a second primary stage I melanoma
distant to the breast which was completely excised. The
3-year rate of contralateral breast cancer events, overall
survival (OS), and breast cancer-specific survival (BCSS)
was 94%, 100%, and 100%, respectively.
Treatment-related toxicities
Radiation dermatitis
During the course of radiotherapy, there were only 2/34
cases of acute grade 2 radiation dermatitis. There were no
observed cases of grade 3–4 acute skin toxicity. Overall,
94% patients developed grade 1 or 2 radiation dermatitis
Enrollment based on pre-
operative eligibility criteria (n = 45)
Definitive surgical 
resection with definitive 
fiducial marker placement 
(n = 45)
Ineligible patients (n = 9)
• Node positive (n = 5)
• Persistent positive margins (n = 1)
• Tumor size >3 cm (n = 2)
• Other (n = 3)
Treated with 3 week APBI 
(n = 34)
Figure 2. Consort diagram for CINJ 040801.

























PR, progesterone receptor; ER, estrogen receptor; HER2, human epi-
dermal growth factor receptor 2; N, node; T, tumor; DCIS, ductal car-
cinoma in situ.
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at treatment completion. Within 1 month after comple-
tion of radiotherapy, the two cases of acute grade 2 radia-
tion dermatitis resolved, and one patient developed moist
desquamation in the UOQ near the axilla (grade 2). At
1 month, 50% of patients who experienced grade 1/2
dermatitis experienced complete resolution of their skin
reaction. There were no observed cases of grade 3–4
sub-acute skin toxicity. Overall, 70% patients developed
hyperpigmentation by 1 month, which persisted at last
follow-up for 50% of these patients.
Fibrosis and subcutaneous toxicities
There were no cases of fibrosis, breast edema, breast pain,
symptomatic seroma, or fat necrosis before, during, or
within 1 month of radiotherapy. There was one case of
grade 2 and one case of grade 3 subcutaneous late toxic-
ity consisting of moderate fibrosis in patients at 3-month
follow-up; the grade 2 toxicity resolved with physical
therapy; the patient with the grade 3 toxicity also devel-
oped breast edema which persisted on longer follow-up
(>2 years). In all, only 3% (1/34) patients experienced a
grade 3 subcutaneous toxicity and breast edema at any
point. Two patients developed chest wall pain which
resolved with physical therapy and massage therapy. One
patient (3%) developed mammographic abnormality at
the primary site; she underwent local excision of this
region for diagnostic purposes and was found to have fat
necrosis. On long-term follow-up of 34 patients, 97% of
the patients had good (45%) to excellent (52%) cosmetic
outcome.
Other toxicities
There was one case of grade 1 radiation pneumonitis
6 weeks following RT, which resolved with steroid treat-
ment. Another patient (3%) developed a symptomatic rib
fracture at 1 year after experiencing blunt force trauma
(grade 2). A separate patient (3%) developed a persistent
and symptomatic seroma requiring multiple aspirations
(grade 2), up to 2 years after radiotherapy. No patient
developed brachial plexopathy, radiation recall, breast
infection, or pericarditis.
Fatigue
Fatigue was measured longitudinally for each patient
prior to, throughout the treatment period, and at follow-
up. Maximum fatigue and average fatigue (from first
OTV to follow-up) was the outcome of interest. In all,
36% of patients developed grade 1 fatigue at the comple-
tion of treatment and 83% patients who developed grade
1 fatigue at the completion of treatment experienced reso-
lution of their fatigue by 1 month. All patients reported
resolution of their fatigue at 1 year posttreatment.
Discussion
This prospective, single-institution study demonstrates
the safety and feasibility of a once daily fractionation
scheme for APBI using 3D-CRT. The 3-year IBTR rate
was 0%, and acute toxicities were minimal. In our cohort
of 34 patients treated with 3.33 Gy for 15 once daily
fractions, the most frequent toxicities (Table 4) observed
(grade 1 or higher) included fibrosis (10%), hyperpig-
mentation (70%), breast edema (3%), telangiectasia
(10%), fat necrosis (3%), symptomatic seroma (3%), and
rib fracture (3%). Only one (3%) grade 3 toxicity (fibro-
sis) was observed in 34 patients at 3 years follow-up and
97% of patients were rated to have good/excellent cos-
metic outcomes. Statistical analyses associating clinical
Table 3. Dosimetric characteristics of study population.
Mean Median St Dev Min Max
Seroma (cc) 48.6 35.4 56.6 10.0 323.0
CTV (cc) 182.1 148.5 121.5 34.0 688.0
PTV_EVAL (cc) 301.2 258.3 177.8 43.7 966.0
Whole breast
volume (cc)
1707.1 1522.5 791.6 405.0 3500.0
Uninvolved breast
volume (cc)
1489.6 1318.1 681.8 320.0 2900.0
V5/UBV 73.5 74.0 13.6 47.0 95.0
V10/UBV 67.0 67.5 14.3 40.0 91.0
V25/UBV 55.8 56.0 12.4 32.0 79.0
V50/UBV 44.6 44.0 10.1 26.0 64.0
V75/UBV 32.2 30.6 9.8 17.0 60.0
V100/UBV 10.7 8.0 10.5 1.0 60.0
CTV coverage
100% IDL
67.8 67.0 16.7 27.0 97.0
CTV coverage
95% IDL
96.8 98.0 4.6 75.0 100.0
PTV coverage
95% IDL
98.5 100.0 2.8 85.0 100.0
Ipsilateral breast coverage (cc)
100% IDL 179.6 150.8 146.4 4.5 523.1
75% IDL 467.0 433.5 237.1 113.6 995.4
50% IDL 650.6 650.4 303.4 136.9 1395.2






106.7 106.9 2.8 101.0 113.0
Dmax (cGy) 5328.8 5339.7 140.7 5045.0 5644.4
CTV, clinical target volume; IDL, isodose line; PD, prescribed dose;
PTV, planning target volume; PTV_EVAL, planning target volume for
evaluation extends to within 5 mm of skin and bound by lung/chest
wall interface; V5/UBV, volume x% of prescription dose divided by
uninvolved breast volume.
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and dosimetric variables to outcome revealed no signifi-
cant correlations. These results, while needing longer fol-
low-up, provide a reasonable alternative to twice daily
APBI fractionation for those patients who find it incon-
venient to travel twice daily for treatment.
A similar fractionation scheme was used by the UK
Start trials when irradiating the whole breast and found
acceptable long-term toxicity and tumor control rates in
patients treated with WBI compared to conventionally
fractionated radiotherapy. In the UK START A trial [8],
2236 women with early breast cancer were randomized to
either 50 Gy in 25 fractions (2 Gy/fx), 39 Gy in 13 frac-
tions (3 Gy/fx), or 41.6 Gy in 13 fractions (3.2 Gy/fx)
directed at the whole breast; however, patients received
five fractions every 2 weeks and approximately 60% of
women also received a conventional 10 Gy (five fraction)
boost. With a median survival of 5.1 years, no significant
differences in local control were detected and toxicity
events such as rib fractures and cardiac events were low in
all arms. Given the relative efficacy and low toxicity of this
hypofractionated whole-breast regimen and the majority
of patients receiving a boost, patients in this protocol were
treated using an APBI fractionation scheme: 49.95 Gy
over 15 single daily fractions (3.33 Gy/fraction). Our frac-
tionation scheme is similar to that of the UK START A
fractionation, but incorporates a standard “boost” portion
using a larger, nonconventional fraction size.
The a/b ratio in the linear quadratic model of fraction-
ation sensitivity describes the relationship between fraction
size and tissue response [9]. Here, “late-reacting” normal
tissues which have a low a/b ratio (2–5 Gy) are very
responsive to increases in fraction size, while “acutely-
reacting” normal tissues have a high a/b ratio (>7 Gy)
and are less responsive to changes in fraction size. Assum-
ing an a/b ratio of 4 Gy for tumor kill, 91.5 Gy4,
90.0 Gy4, and 99.2 Gy4 was estimated to be delivered
using our fractionation scheme, standard WBI + boost,
and the Owens fractionation, respectively. Assuming an
a/b ratio of 10 Gy for acute effects, 66.6 Gy10, 72.0 Gy10,
and 73.9 Gy10 was estimated to be delivered using our
fractionation scheme, standard WBI + boost, and the
Owens fractionation, respectively.
It is interesting to note, however, that the ‘standard’
APBI twice daily regimen of 38.5 Gy over 10 twice daily
fractions (3.85 Gy/fraction) was developed to deliver an
equivalent dose of 50 Gy over 25 single daily fractions
(2 Gy/fraction) [10]. This effectively omits the boost
portion of the treatment, which has been shown to be
effective to reduce the rate of IBTR in patients with
invasive disease [11, 12]. Thus, we find that the BED of
twice daily APBI and standard WBI (50 Gy) is 76.0 Gy4
and 75.0 Gy4, respectively, compared to 90.0 Gy4 for
standard WBI + boost (60 Gy), when using an a/b ratio
of 4 Gy for tumor kill. Interestingly, given that relatively
little cellular proliferation will occur during the course of
the 5 days, the lack of tumor repopulation which may
occur during standard 5–7 week WBI schedules offers an
apparent advantage to use of this 5-day APBI schedule.
Furthermore, the BED calculation used for the 5-day
APBI assumed that full repair of sublethal damage
between fractions had occurred when using an interfrac-
tion interval of 6 h. Thus, the calculated BED of this
regimen does not account for an incomplete repair fac-
tor and while many patients may empirically meet this
standard, we are unable to determine the exact BED for
the 5-day APBI schedule. In addition, the origin of the
5-day APBI stems from the brachytherapy data where
there is good reason to take the catheters out in as short
a time as possible, due to the risk of infection. This is
not an issue with 3D-CRT, so given patient convenience,
potential toxicity issues, and logistics a once daily regi-
men, albeit a longer treatment length, is a reasonable
approach.
Brachytherapy has been used to deliver APBI well
before 3D-CRT and offers the longest follow-up with
respect to outcomes and toxicity [13–15]. Since the devel-
opment of 3D-CRT based APBI, there have been single-
institution reports of poor cosmetic outcomes and late
toxicities using 3D-CRT. Wazer and colleagues reported
on a cohort of 60 patients treated with 3D-CRT in strict
accordance to the RTOG 0413 protocol. With a median
follow-up of 15 months, 10% of patients developed grade
Table 4. Incidence of any treatment-related toxicities over past
3 years.
Toxicity1 Grade 0 Grade 1 Grade 2 Grade 3
Pericarditis 34 0 0 0
Pneumonitis 33 1 0 0
Radiation recall 34 0 0 0
Breast infection 34 0 0 0
Fatigue 26 12 0 0
Radiation dermatitis 0 32 2 0
Seroma 31 2 1 0
Hyperpigmentation 9 25 0 0
Breast edema 32 0 1
Fibrosis 31 1 1 1
Brachial plexopathy 34 0 0 0
Rib fracture 33 0 1 0
Fat necrosis 33 0 1 0
Chest wall pain 32 0 2 0
1Toxicities scored on the National Cancer Institute’s form for Common
Toxicity Criteria for Adverse Events (CTCAE), v4.0. Acute toxicities are
defined as those noted on the CTCAE forms completed from begin-
ning of treatment to up to 1 month follow-up. Late toxicities are
defined as those noted on the CTCAE forms completed at the
3 month or subsequent follow-up visits.
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3–4 late toxicities and 18.4% of patients experienced a
fair-poor cosmetic outcome. They performed a retrospec-
tive dosimetric analysis which demonstrated the larger
low-dose volumes of the breast correlated significantly
with the development of fibrosis.
Jagsi et al. [2] published on a cohort of 34 patients trea-
ted with APBI using intensity-modulated radiation therapy
(IMRT) and active breathing control using the “standard”
APBI twice daily regimen of 38.5 Gy over 10 twice daily
fractions (3.85 Gy/fraction). However, after new unaccept-
able cosmesis developed in seven patients, the study was
closed early. Of their seven patients with overall unaccept-
able cosmesis, all had volume loss affecting cosmesis, six
had retraction or contour defect affecting cosmesis, and
one had telangiectasias affecting cosmesis. They concluded
that hypofractionated schedule and parameters commonly
used for external beam APBI may be suboptimal when
using highly conformal techniques such as IMRT or respi-
ratory gating. It should be noted that IMRT and gating
technique are not allowed on the National Surgical Adju-
vant Breast and Bowel Project B-39 & Radiation Therapy
Oncology Group 0413 APBI protocol.
Shah et al. [16] reported the Beaumont experience of
192 patients treated with 3D-CRT-based APBI with a
median follow-up of 4.8 years. At 5 years, the rate of
IBTR, regional recurrence, cause-specific survival, and OS
were 0%, 0%, 99%, and 92%, respectively. Excellent/good
cosmesis was found in 81% of patients and the reported
rates of grade III fibrosis and telangiectasia were 7.5%
and 7.6%, respectively.
A prone-APBI experience utilizing a once daily fraction
size was reported by Formenti and colleagues at the New
York University. They designed a Phase I/II study in 2000
evaluating the role of APBI delivered using 3D-CRT to 46
patients laying in the prone position delivering a total
dose of 30 Gy at 6 Gy/fraction in five fractions over
10 days to the tumor bed plus a 1.5–2-cm margin [17,
18]. With a median follow-up of 18 months, they
reported that acute toxicity was limited mainly to grade
1–2 erythema and only grade 1 late toxicity occurred.
Cosmesis was rated as good/excellent in 92% of patients.
However, given that prone positioning is not commonly
used, the use of the fractionation scheme in the supine
position may result in different dosimetric outcomes and
may not afford the same dosimetric advantages that may
be seen with prone positioning.
In conclusion, our accelerated partial breast fraction-
ation scheme of 15 once daily fractions of 3.33 Gy
(49.95 Gy total) is a remarkably well-tolerated regimen of
3D-CRT-based APBI. However, differences in toxicity
grading and reporting, treatment planning/target volume
definitions, and intrinsic differences in patient populations
may lead to the disparities seen among the reports dis-
cussed above. In addition, limited long-term follow-up
demonstrates good to excellent cosmetic outcome and low
rates of late complications for patients treated with this
fractionation schedule. Longer follow-up is needed to fur-
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